Ceretas Limited
ABN 15 681 662 224

INTERIM CONDENSED FINANCIAL STATEMENTS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

Contents to the Interim Condensed Financial Statements

Corporate Directory

Directors
Mr John Keep
Dr Rachel de las Heras
Dr Anthony Keating
Mr Sam Wetzler
Dr Stuart Crozier

Company Secretary
Ms Nicki Farley

Principal Office
Level 4, 260 Queen Street
Brisbane QLD 4000

Registered Office
Level 4, 260 Queen Street
Brisbane QLD 4000

Auditors
BDO Audit Pty Ltd
Level 18, 360 Queen Street.
Brisbane QLD 4000

Directors' Report

The Directors of Ceretas Limited ("the Company") submit herewith their report of the Company for the half-year ended 31 December 2025.

Principal Activities

During the financial period the principal activities of the Company consisted of research and development of a novel therapeutic ultrasound technology licensed from UniQuest Pty Limited ('UniQuest') (the 'Ceretas Technology'), for the purpose of commercialising a portable, image-guided therapeutic ultrasound platform designed for the treatment of neurodegenerative disease, in particular Alzheimer's disease.

Operating Results and Financial Position

The loss for the Company for the half-year ended 31 December 2025 was $361,022 (for the period from 21 October 2024 to 31 December 2024: $17,489).

During the half-year, the Company generated total income of $688,050 (for the period from 21 October 2024 to 31 December 2024: $Nil), primarily comprising grant income of $673,449 and interest income of $14,601. Operating expenses totalled $1,049,072 (for the period from 21 October 2024 to 31 December 2024 $17,489), with the majority relating to research and development costs of $673,532 and general and administrative expenses of $375,540.

Net operating cash inflow for the half-year was $641,727 (for the period from 21 October 2024 to 31 December 2024: net cash outflow of $15,217), reflecting the receipt of grant funding during the half-year. Net cash used in investing activities was $98,224, primarily relating to the acquisition of equipment.

Net cash inflow from financing activities was $1,488,477 (for the period from 21 October 2024 to 31 December 2024: $47,580), driven mainly by $1,500,000 received in share application funds. On 5 January 2026, the Company issued 9,375,000 shares for of the $1,500,000 of share application funds (before share issue costs) received before the period end at an issue price of $16 cents per share.

As at 31 December 2025, the Company had net assets of $2,261,816 (30 June 2025: $1,202,800). This included cash and cash equivalents of $2,885,917 and an intangible asset of $362,222 relating to the licensed intellectual property for the Ceretas Technology.

In July 2025, Ceretas has been awarded a $2,390,000 grant under the Australian Government's MRFF CUREator+ Dementia & Cognitive Decline program to accelerate development of its next-generation therapeutic ultrasound device for Alzheimer's disease. The funding will support advancement of the Australian-designed technology aimed at improving memory and cognition in patients with neurodegenerative conditions.

In October 2025, the Company granted 890,000 options over ordinary shares in the Company to employees of the Company. The Options will vest following the Company's successful admission to the official list of the ASX and the satisfaction certain vesting conditions. The options have an exercise price equal to a 50% premium to the IPO price and an expiry date of five years from the date of the IPO.

Unissued ordinary shares of Ceretas Limited under option at the date of this report are as follows:

Grant date	Expiry date	Exercise price	Number under option
10 October 2025	10 October 2030	$0.375	240,000
27 October 2025	27 October 2030	$0.375	650,000

Directors' Report

Rounding of amounts

The Company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar.

Auditor's Independence Declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

Signed in accordance with a resolution of the directors

John Keep
Director

Brisbane
18th day of May 2026

Tel: +61 7 5456 7999
Fax: +61 7 5456 7905
www.bdo.com.au

Level 3/2 Emporio Place
2 Maroochy Boulevard
Maroochydore QLD 4558
PO Box 5800 Maroochydore QLD 4558
Australia

DECLARATION OF INDEPENDENCE BY ALLEN TONGOL TO THE DIRECTORS OF CERETAS LIMITED

As lead auditor for the review of Ceretas Limited for the half-year ended 31 December 2025, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

Allen Tongol

Director

BDO Audit Pty Ltd

Maroochydore, 18 May 2026

Interim Condensed Statement of Profit or Loss and Other Comprehensive Income
For the Half-Year Ended 31 December 2025

	Note	**31 December 2025**	21 October to 31 December 2024
			$
Government grant income	2	**673,449**	–
Interest income		**14,601**	–
		688,050	–
Research and development	3	**(673,532)**	–
General and administration	4	**(375,540)**	(17,489)
Loss before income tax expense		**(361,022)**	(17,489)
Income tax expense		**–**	–
Loss after income tax expense		**(361,022)**	(17,489)
Other comprehensive income for the period, net of tax		**–**	–
Total comprehensive loss for the period		**(361,022)**	(17,489)
Loss per share (basic and diluted) (cents)	12	(1.24)	(0.29)

The above Interim Condensed Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

Interim Condensed Statement of Financial Position
As at 31 December 2025

	Note	31 December 2025 $	30 June 2025 $
Current assets			
Cash and cash equivalents	5	**2,885,917**	853,937
GST receivable		**–**	5,441
Other current asset		**8,940**	3,100
Total current assets		**2,894,857**	862,478
Non-current assets			
Equipment	6	**97,232**	–
Intangible asset (Licensed IP)	7	**362,222**	388,889
Total non-current assets		**459,454**	388,889
Total assets		**3,354,311**	1,251,367
Current liabilities			
Trade and other payables	8	**350,588**	31,359
Deferred government grant income	9	**720,361**	–
Employee benefits provision		**21,546**	5,685
Borrowings	13	–	11,523
Total current liabilities		**1,092,495**	48,567
Total liabilities		**1,092,495**	48,567
Net assets		**2,261,816**	1,202,800
Equity			
Issued capital		**1,386,180**	1,386,180
Share application funds	10	**1,410,000**	–
Share-based payment reserve	11	**10,038**	–
Accumulated losses		**(544,402)**	(183,380)
Total equity		**2,261,816**	1,202,800

The above Interim Condensed Statement of Financial Position should be read in conjunction with the accompanying notes.

Interim Condensed Statement of Changes in Equity
For the Half-Year Ended 31 December 2025

	Fully paid ordinary shares $	Share application funds $	Share-based payment reserve $	Accumulated losses $	Total $
Balance at 21 October 2024	–	–	–	–	–
Loss for the period	–	–	–	(17,489)	(17,489)
Total comprehensive loss	–	–	–	**(17,489)**	**(17,489)**
Transactions with owners, in their capacity as owners					
Issue of shares	580	–	–	–	580
Balance at 31 December 2024	**580**	–	–	**(17,489)**	**(16,909)**
Balance at 1 July 2025	**1,386,180**	–	–	**(183,380)**	**1,202,800**
Loss for the period	–	–	–	(361,022)	(361,022)
Total comprehensive loss	–	–	–	**(361,022)**	**(361,022)**
Transactions with owners, in their capacity as owners					
Share application funds (Note 10)	–	1,500,000	–	–	1,500,000
Costs directly attributable to share application funds	–	(90,000)	–	–	(90,000)
Share-based payments	–	–	10,038	–	10,038
Balance at 31 December 2025	**1,386,180**	**1,410,000**	**10,038**	**(544,402)**	**2,261,816**

The above Interim Condensed Statement of Changes in Equity should be read in conjunction with the accompanying notes.

Interim Condensed Statement of Cash Flows
For the Half-Year Ended 31 December 2025

	Note	31 December 2025 $	21 October to 31 December 2024 $
Cash flows from operating activities			
Cash payments to suppliers and employees (inclusive of GST)		**(900,225)**	(15,217)
Grant income received		**1,533,191**	–
Interest received		**14,601**	–
Lease deposit		**(5,840)**	–
Net cash flows from (used in) operating activities		**641,727**	(15,217)
Cash flows from investing activity			–
Purchase of equipment		**(98,224)**	–
Net cash flows used in investing activity		**(98,224)**	–
Cash flows from financing activities			
Proceeds from share application funds	10	**1,500,000**	–
Proceeds from (repayment of) borrowings		**(11,523)**	47,000
Proceeds from issues of share capital		**–**	580
Net cash flows provided by financing activities		**1,488,477**	47,580
Net increase in cash and cash equivalents		**2,031,980**	32,363
Cash and cash equivalents at beginning of period		**853,937**	–
Cash and cash equivalents at end of period	5	**2,885,917**	32,363

The above Interim Condensed Statement of Cash Flows should be read in conjunction with the accompanying notes.

Notes to the Interim Condensed Financial Statements
For the *Half-Year Ended 31 December 2025*

Note 1 Material accounting policy information

These general-purpose financial statements for the half-year 31 December 2025 have been prepared in accordance with Australian Accounting Standard AASB 134 *'Interim Financial Reporting'* and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 *'Interim Financial Reporting'*.

These general-purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the financial statements for the year 30 June 2025.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

The financial statements were approved by the Board on 18th May 2026.

Rounding of amounts

The Company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest dollar, or in certain cases, the nearest dollar.

New or amended Accounting Standards and Interpretations adopted

The Company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

New standards and interpretations not yet adopted

Certain new accounting standards and interpretations have been published that are not mandatory for 31 December 2025 reporting periods and have not been early adopted by the Company. The Company expects that only AASB 18 *Presentation and Disclosures in Financial Statements* may have an impact on income and expense presentation in the statement of profit or loss and other comprehensive income and additional disclosures on management-defined performance measures in the notes to the financial statements. The Company has not assessed the impact of the new standard.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Going Concern

For the half-year ended 31 December 2025, the Company recorded a loss of $361,022 (2024: $17,489).

The ability of the Company to maintain continuity of normal business activities and to pay its debts as and when they fall due is dependent on the ability of the Company to successfully raise additional capital and/or successful development and commercialisation of its Ceretas Technology.

There is a material uncertainty that may cast a significant doubt about the Company's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business and at the amounts stated in the financial statements. The financial report does not include any adjustments relating to the amounts or classification of recorded assets or liabilities that might be necessary if the Company does not continue as a going concern.

Management believe there are sufficient funds to meet the Company's working capital requirements for the next twelve months from the date the financial statements were authorised for issue. Subsequent to period end the

Notes to the Interim Financial Statements (continued)
For the Half-Year Ended 31 December 2025

Company expects to raise additional funds via either a placement to new or existing investors or by conducting an entitlement issue with existing shareholders.

The financial statements have been prepared on the basis that the entity is a going concern, which contemplates the continuity of normal business activity, realisation of assets and settlement of liabilities in the normal course of business for the following reasons:

- The Company intends to complete its Initial Public Offering in mid calendar year 2026 in which it intends to raise $8,000,000;
- In July 2025, the Company was awarded a CUREATOR+ Dementia & Cognitive Decline grant amounting to $2,390,000. Of this amount, $996,190 remains to be received as at 31 December 2025. The Company will comply with the requirements of the grant agreement to receive funding from the Commonwealth government and the project participants;
- On 5 January 2026, the Company successfully completed a capital raising of $1,500,000, issuing 9,375,000 new fully paid ordinary shares at an issue price of $16 cents per share;
- The Company's Research and Development activities are expected to be eligible for the Australian Government's Research and Development (R&D) Tax Incentive Scheme, which provides refundable tax offsets for eligible R&D expenditure;
- The Company also has the ability to reduce its expenditure to conserve cash.

Should the Company not be able to continue as a going concern, it may be required to realise its assets and discharge its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements and that the financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or liabilities that might be necessary should the entity not continue as a going concern.

Note 2 Government grant income

	31 December 2025	21 October to 31 December 2024
	$	$
CUREator + Dementia & Cognitive Decline Grant	**673,449**	–

In July 2025, the Company has been awarded a $2,390,000 grant under the Australian Government's MRFF CUREator+ Dementia & Cognitive Decline program to accelerate development of its next-generation therapeutic ultrasound device for Alzheimer's disease. The funding will support advancement of the Australian-designed technology aimed at improving memory and cognition in patients with neurodegenerative conditions.

Government Grant Income Recognition
As of the date of this report, the Company has received a total of $1,393,810 in funding from the CUREator+ Dementia & Cognitive Decline grant program. Out of this total, $673,449 was recognised as "Government grantincome" in the profit or loss for the half-year ended December 31, 2025. The remaining amount of $720,361 was recorded as "Deferred government grant income" on the statement of financial position as of 31 December 2025. The income recognised corresponds to the costs that the grant was intended to compensate.

Notes to the Interim Financial Statements (continued)
For the Half-Year Ended 31 December 2025

Note 3 Research and development

	31 December 2025	21 October to 31 December 2024
	$	$
Employee benefits costs	**258,087**	–
Contractors' costs	**301,554**	–
Consumables	**60,271**	–
Depreciation and amortisation	**27,659**	–
Share-based payments	**10,038**	–
Others	**15,923**	–
	673,532	–

Note 4 General and administration

	31 December 2025	21 October to 31 December 2024
	$	$
Employee benefits costs	**72,778**	–
Contractors' costs	**30,800**	–
Professional and legal fees	**168,524**	–
Others	**103,438**	17,489
	375,540	17,489

Note 5 Cash and cash equivalents

	31 December 2025	30 June 2025
	$	$
Cash deposits on demand	**2,885,917**	853,937

Note 6 Equipment

During the half-year ended 31 December 2025, the Company acquired equipment with a total cost of $98,224 and recognised depreciation expense of $992.

Note 7 Intangible asset

During the half-year ended 31 December 2025, the Company recognised amortisation expense of $26,667.

Notes to the Interim Financial Statements (continued)
For the Half-Year Ended 31 December 2025

Note 8 Trade and other payables

	31 December 2025	30 June 2025
	$	$
Trade payables	**223,858**	11,489
Accrued expenses	**72,632**	15,000
GST payable	**19,852**	–
PAYG withholding payable	**15,076**	4,870
Superannuation payable	**19,170**	–
	350,588	31,359

Note 9 Deferred government grant income

Deferred government grant income of $720,361 as at 31 December 2025 (30 June 2025: Nil) represents funding received under the CUREator+ Dementia & Cognitive Decline program for which the related eligible research and development expenditure has not yet been incurred.

Government grant income is recognised in profit or loss in accordance with AASB 120 *Accounting for Government Grants and Disclosure of Government Assistance*, over the periods in which the Group recognises the related expenses that the grant is intended to compensate.

The Group has assessed that there is reasonable assurance that it will comply with the conditions attached to the grant and that the grant will be received.

No other material changes to the terms or conditions of government funding arrangements have occurred during the half-year.

Note 10 Share application funds

During the half-year ended 31 December 2025, the Company received $1,500,000 (before transaction costs) in relation to a capital raising. As at 31 December 2025, the shares associated with these funds had not yet been formally issued.

On 5 January 2026, the Company issued the relevant shares and the balance was reclassified within equity to issued capital. Transaction costs associated with the capital raising amounting $90,000 are recognised as a deduction from issued capital (See Note 13).

Note 11 Share-based payments

The Company operates an equity-settled share-based payment plan under which options are granted to employees and key management personnel. Options vest subject to service conditions and successful admission to the ASX.

The fair value of options is determined at grant date using the Black-Scholes model and recognised over the vesting period.

Notes to the Interim Financial Statements (continued)
For the Half-Year Ended 31 December 2025

During the half-year 31 December 2025, the Company granted the following options:

- 890,000 Employee Incentive Options were granted to employees in October 2025 pursuant to the terms of the Company's Employee Securities Incentive Plan. The Options are exercisable at a 50% premium to the price of the Company's IPO Price and expire in October 2030. The Options will vest following the Company's successful admission to the official list of the ASX and the satisfaction of the relevant Vesting Conditions over 3 years from the date of start of employment if the employee remains employed by the Company. The options are valued at the date of grant and recognised over the vesting period.

	Number of Options	**Share-based payment Reserve $**
Balance as at 1 July 2025		
Options issued during the period	890,000	10,038
Balance as at 31 December 2025	**890,000**	**10,038**

Grant date	Dividend yield	Expected volatility	Risk-free interest rate	Option exercise price	Expected life (years)	Share price on date of grant	Fair value on grant date
27-Oct-25	0%	100%	4.640%	0.375	5	0.16	0.104
10-Oct-25	0%	100%	4.640%	0.375	5	0.16	0.104

The share price is based on the 31 December 2025 capital raise. The IPO condition is a non-market performance condition and is excluded from fair value.

Share-based payment expense of $10,038 (2024: $nil) was recognised during the period.

Note 12 Loss per share

The earnings and weighted average number of ordinary shares used in the calculation of basic loss per share are as follows:

	2025 $	2024 $
Loss attributable to ordinary equity holders (used in calculating basic and diluted EPS) – continuing operations.	**(361,022)**	(17,489)
Weighted average number of ordinary shares for the purpose of basic and diluted earnings per share adjusted for share consolidation	**29,000,000**	6,116,206
Loss per share (basic and diluted) (cents)	**(1.24)**	(0.29)

Notes to the Interim Financial Statements (continued)
For the Half-Year Ended 31 December 2025

Note 13 Related party transactions

Transactions with key management personnel and related parties

During the period, the Company entered into the following transactions with key management personnel and related parties:

- Loans advanced by Directors amounting to $11,523, which are non-interest bearing, unsecured and repayable on demand. The borrowings were fully repaid at reporting date.
- $90,000 (30 June 2025: $60,000) in capital raising fees due to Caravel Securities Pty Ltd, an entity controlled by a director who served during the reporting period (and subsequently resigned) received a transaction fee of 6% of funds raised in connection with capital raising activities, pursuant to a mandate agreement to provide capital raising and corporate advisory services. This balance remains outstanding as at 31 December 2025 and is recorded in trades payable.
- Subscriptions for new ordinary shares by key management personnel, directors, and their related entities amounted to $160,000 and have been recognised as share application funds, as the shares have not yet been issued as at 31 December 2025.

Other than those transactions noted above, there were no related party transactions that occurred in the reporting period.

Note 14 Contingent liabilities

The Directors of the Company are not aware of any contingent liabilities which require disclosure in the half-year 31 December 2025.

Note 15 Commitments

	31 December 2025 $	30 June 2025 $
Not later than 1 year		
Research and development commitments	**23,759**	–
Total research and development commitments	**23,759**	–

Note 16 Segment Information

<u>Operating Segments</u>
The Company has considered the requirements of AASB 8, *Operating Segments* and has identified its operating segments based on the internal reports that are reviewed and used by management and the board of directors (chief operating decision makers) in assessing performance and determining the allocation of resources.

The Company operates as a single segment being research and development of a non-invasive, safe and portable therapeutic ultrasound platform to treat neurodegenerative diseases. The chief operating decision makers review the performance and financial position of the Company. There is no difference between the audited financial report and the internal reports generated for review. The Company is domiciled in Australia and is currently in the development phase and hence has not begun to generate revenue from operations. All assets are located in Australia.

Note 17 Events after the reporting period

On 5 January 2026, the Company issued 9,375,000 shares for the $1,500,000 share application funds (before share issue costs) received before the period end at an issue price of $16 cents per share.

On 27 March 2026, the Directors resolved by circular resolution to adopt a Revised Employee Securities Incentive Plan (Revised ESIP), replacing the Company's Original Employee Securities Incentive Plan (Original ESIP) with effect from that date. As a result, the 890,000 Options granted in October 2025 under the original ESIP will be replaced in accordance with the terms and conditions of the Revised ESIP.

On 29 April 2026, the Company approved the allocation, under the Revised ESIP, of 5,580,000 Options and 2,500,000 Performance Rights to directors, management and employees, intended to be issued immediately prior to the Company's proposed ASX listing. All Options will be exercisable at a price representing a 50% premium to the IPO price (being $0.375 per Option) and will expire 5 years from the date of issue. All Performance Rights are subject to performance milestones approved by ASX.

No other adjusting or significant non-adjusting events have occurred between the reporting date and the date of authorisation.

Directors' Declaration

In the opinion of the Directors of Ceretas Limited ("the Company"):

1. The accompanying interim condensed financial statements and notes for the half-year ended 31 December 2025:

   (a) comply with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001* and other mandatory professional reporting requirements; and

   (b) give a true and fair view of the Company's financial position as at 31 December 2025 and of its performance for the half-year ended on that date.

2. There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

John Keep
Director

Brisbane
18th day of May 2026

Tel: +61 7 5456 7999
Fax: +61 7 5456 7905
www.bdo.com.au

Level 3/2 Emporio Place
2 Maroochy Boulevard
Maroochydore QLD 4558
PO Box 5800 Maroochydore BC QLD 4558
Australia

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Ceretas Limited

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of Ceretas Limited (the Company), which comprises the statement of financial position as at 31 December 2025 *and 30 June 2025*, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows *for the half-years ended on 31 December 2025 and 31 December 2024*, material accounting policy information and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Company does not comply with the *Corporations Act 2001* including:

i. Giving a true and fair view of the company's financial position as at 31 December 2025 and of its financial performance for the half-year ended on that date; and
ii. Complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (including Independence Standards) (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

Material uncertainty relating to going concern

We draw attention to Note 1 in the financial report which describes the events and/or conditions which give rise to the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern and therefore the Company may be unable to realise its assets and discharge its liabilities in the normal course of business. Our conclusion is not modified in respect of this matter.

Responsibility of the directors for the financial report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Company's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit Pty Ltd

BDO

Allen Tongol
Director

Maroochydore, 18 May 2026